Condition: Major Depressive Disorder · Sponsor: Xenon Pharmaceuticals Inc.
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
This description comes directly from the study's public registry record.
Xenon Medical Affairs · 1-604-484-3300 · XenonCares@xenon-pharma.com
Always discuss trial participation with your own doctor first.
| Harmonex Neuroscience Research | Dothan, Alabama, United States | Terminated |
| University of Alabama at Birmingham, Huntsville Regional Medical Campus | Huntsville, Alabama, United States | Recruiting |
| Pillar Clinical Research | Bentonville, Arkansas, United States | Recruiting |
| SanRo Clinical Research Group | Bryant, Arkansas, United States | Recruiting |
| Clinical Innovations Inc | Bellflower, California, United States | Recruiting |
| Center for Neurohealth | La Jolla, California, United States | Recruiting |
| Artemis Institute for Clinical Research | San Diego, California, United States | Recruiting |
| California Neuroscience Research | Sherman Oaks, California, United States | Recruiting |
| Pacific Clinical Research Management Group | Upland, California, United States | Terminated |
| Institute of Living | Hartford, Connecticut, United States | Recruiting |
| Gulfcoast Clinical Research Center | Fort Myers, Florida, United States | Recruiting |
| Sarkis Clinical Trials | Gainesville, Florida, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07076407